{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:19:13Z","timestamp":1794439153411,"version":"4.9.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"38","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Randomized clinical trials (RCTs) assessing semaglutide reported reductions of systolic blood pressure (SBP) in trial populations with baseline blood pressure in the normotensive range. This study aimed to determine whether this SBP reduction is greater in hypertensive groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Individual patient data (IPD) from three RCTs examining the effect of semaglutide 2.4\u2005mg on body weight over 68 weeks were included. Trial participants were categorized according to a hypertension diagnosis, treatment or baseline measurement (HTN), baseline SBP &amp;gt; 130\u2005mmHg (HTN130) or &amp;gt;140\u2005mmHg (HTN140), and those with apparent resistant hypertension (RH). The primary analysis compared the in-trial change in SBP in the semaglutide and placebo arms. Alterations of anti-hypertensive medications were quantified by treatment intensity score and compared between arms. These analyses were performed using analysis of covariance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 3136 participants were included. The difference in SBP change between the treatment (n = 2109) and placebo (n = 1027) groups was \u22124.95\u2005mmHg [95% confidence interval (CI) \u22125.86 to \u22124.05] overall. This difference was \u22124.78\u2005mmHg (95% CI \u22125.97 to \u22123.59) for HTN, \u22124.93\u2005mmHg (95% CI \u22126.75 to \u22123.11) for HTN130, \u22124.09\u2005mmHg (95% CI \u22127.12 to \u22121.06) for HTN140, and \u22123.16\u2005mmHg (95% CI \u22128.69\u20132.37) for RH. Reduction in SBP was mediated substantially by weight loss. The anti-hypertensive treatment intensity score decreased for those on semaglutide compared to placebo (\u22120.51; 95% CI \u22120.71 to \u22120.32).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This IPD analysis of three large RCTs found blood pressure reductions with semaglutide in participants with hypertension that were similar to those seen in all trial participants. This finding may in part be due to concurrent reductions to anti-hypertensive medications. These results suggest that semaglutide is a useful adjunctive treatment for patients with hypertension and obesity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehae564","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T10:01:10Z","timestamp":1723802470000},"page":"4124-4134","source":"Crossref","is-referenced-by-count":62,"title":["Semaglutide and blood pressure: an individual patient data meta-analysis"],"prefix":"10.1093","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2577-0242","authenticated-orcid":false,"given":"Cormac","family":"Kennedy","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Therapeutics, School of Medicine, Trinity College Dublin , Dublin D02 PN40 ,","place":["Ireland"]},{"name":"Wellcome-HRB Clinical Research Facility, St James's Hospital , Dublin D08 NHY1 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hayes","sequence":"additional","affiliation":[{"name":"Health Research Institute, University of Limerick ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4367-3884","authenticated-orcid":false,"given":"Arrigo F G","family":"Cicero","sequence":"additional","affiliation":[{"name":"Hypertension and Cardiovascular Risk Research Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum\u2014University of Bologna , Bologna ,","place":["Italy"]},{"name":"Cardiovascular Medicine Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2220-9799","authenticated-orcid":false,"given":"Stephan","family":"Dobner","sequence":"additional","affiliation":[{"name":"3rd Medical Department of Cardiology and Intensive Care Medicine, Clinic Ottakring (Wilhelminenhospital) , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5521-5445","authenticated-orcid":false,"given":"Carel W","family":"Le Roux","sequence":"additional","affiliation":[{"name":"Diabetes Complications Research Centre, Conway Institute, University College Dublin , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6530-5479","authenticated-orcid":false,"given":"John W","family":"McEvoy","sequence":"additional","affiliation":[{"name":"University of Galway and National Institute of Prevention and Cardiovascular Health , Galway ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4089-9703","authenticated-orcid":false,"given":"Lina","family":"Zgaga","sequence":"additional","affiliation":[{"name":"Department of Public Health and Primary Care, School of Medicine, Trinity College Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Hennessy","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, School of Medicine, Trinity College Dublin , Dublin D02 PN40 ,","place":["Ireland"]},{"name":"Wellcome-HRB Clinical Research Facility, St James's Hospital , Dublin D08 NHY1 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,1]]},"reference":[{"key":"2024100721243506900_ehae564-B1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/HYPERTENSIONAHA.119.13437","article-title":"Future of hypertension","volume":"74","author":"Dzau","year":"2019","journal-title":"Hypertension"},{"key":"2024100721243506900_ehae564-B2","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","author":"Zhou","year":"2021","journal-title":"Lancet"},{"key":"2024100721243506900_ehae564-B3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40292-020-00359-0","article-title":"Blood pressure targets achievement according to 2018 ESC\/ESH guidelines in three European excellence centers for hypertension","volume":"27","author":"Tocci","year":"2020","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"2024100721243506900_ehae564-B4","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41371-021-00644-y","article-title":"Highlights of mechanisms and treatment of obesity-related hypertension","volume":"36","author":"Shams","year":"2022","journal-title":"J Hum Hypertens"},{"key":"2024100721243506900_ehae564-B5","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1161\/CIRCRESAHA.116.305697","article-title":"Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms","volume":"116","author":"Hall","year":"2015","journal-title":"Circ Res"},{"key":"2024100721243506900_ehae564-B6","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMra1514009","article-title":"Mechanisms, pathophysiology, and management of obesity","volume":"376","author":"Heymsfield","year":"2017","journal-title":"N Engl J Med"},{"key":"2024100721243506900_ehae564-B7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.pcad.2018.07.005","article-title":"Obesity and kidney disease","volume":"61","author":"Lakkis","year":"2018","journal-title":"Prog Cardiovasc Dis"},{"key":"2024100721243506900_ehae564-B8","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1161\/HYP.0000000000000202","article-title":"Weight-loss strategies for prevention and treatment of hypertension: a scientific statement from the American Heart Association","volume":"78:","author":"Hall","year":"2021","journal-title":"Hypertension"},{"key":"2024100721243506900_ehae564-B9","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41371-021-00630-4","article-title":"Is it time to reconsider the treatment paradigm for obese patients with hypertension?","volume":"36","author":"Kennedy","year":"2021","journal-title":"J Hum Hypertens"},{"key":"2024100721243506900_ehae564-B10","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"2024100721243506900_ehae564-B11","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1007\/s11845-021-02870-2","article-title":"Clinical characteristics of two groups commonly referred to an Irish hypertension service\u2014patients with resistant hypertension and young adults with hypertension","volume":"191","author":"Kennedy","year":"2022","journal-title":"Ir J Med Sci"},{"key":"2024100721243506900_ehae564-B12","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1161\/HYPERTENSIONAHA.110.168948","article-title":"Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring","volume":"57","author":"de la","year":"2011","journal-title":"Hypertension"},{"key":"2024100721243506900_ehae564-B13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41371-021-00514-7","article-title":"Referrals to, and characteristics of patients attending a specialist hypertension clinic","volume":"36","author":"Kennedy","year":"2021","journal-title":"J Hum Hypertens"},{"key":"2024100721243506900_ehae564-B14","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2024100721243506900_ehae564-B15","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3390\/jcm12030772","article-title":"The effect of semaglutide on blood pressure in patients without diabetes: a systematic review and meta-analysis","volume":"12","author":"Kennedy","year":"2023","journal-title":"J Clin Med"},{"key":"2024100721243506900_ehae564-B16","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O'Neil","year":"2018","journal-title":"Lancet"},{"key":"2024100721243506900_ehae564-B17","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"key":"2024100721243506900_ehae564-B18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"2024100721243506900_ehae564-B19","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"2024100721243506900_ehae564-B20","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"2024100721243506900_ehae564-B21","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"2024100721243506900_ehae564-B22","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.jash.2016.10.005","article-title":"Total antihypertensive therapeutic intensity score and its relationship to blood pressure reduction","volume":"10","author":"Levy","year":"2016","journal-title":"J Am Soc Hypertens"},{"key":"2024100721243506900_ehae564-B23","doi-asserted-by":"publisher","first-page":"e2034059","DOI":"10.1001\/jamanetworkopen.2020.34059","article-title":"A method to quantify mean hypertension treatment daily dose intensity using health care system data","volume":"4","author":"Min","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2024100721243506900_ehae564-B24","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1161\/01.HYP.37.2.250","article-title":"Hypothesis: \u03b2-adrenergic receptor blockers and weight gain: a systematic analysis","volume":"37","author":"Sharma","year":"2001","journal-title":"Hypertension"},{"key":"2024100721243506900_ehae564-B25","author":"World Health Organisation"},{"key":"2024100721243506900_ehae564-B26","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1161\/HYPERTENSIONAHA.123.22022","article-title":"Tirzepatide reduces 24-hour ambulatory blood pressure in adults with body mass index \u2265 27\u2005kg\/m2: SURMOUNT-1 ambulatory blood pressure monitoring substudy","volume":"81","author":"De Lemos","year":"2024","journal-title":"Hypertension"},{"key":"2024100721243506900_ehae564-B27","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1161\/01.HYP.0000094221.86888.AE","article-title":"Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials","volume":"42","author":"Neter","year":"2003","journal-title":"Hypertension"},{"key":"2024100721243506900_ehae564-B28","doi-asserted-by":"publisher","first-page":"CD008274","DOI":"10.1002\/14651858.CD008274.pub4","article-title":"Long-term effects of weight-reducing diets in people with hypertension","volume":"2","author":"Semlitsch","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2024100721243506900_ehae564-B29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12933-023-01775-x","article-title":"Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes","volume":"22","author":"Ferdinand","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2024100721243506900_ehae564-B30","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Mede"},{"key":"2024100721243506900_ehae564-B31","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2307\/2094540","article-title":"The Hawthorne experiments: first statistical interpretation","volume":"43","author":"Franke","year":"1978","journal-title":"Am Sociol Rev"},{"key":"2024100721243506900_ehae564-B32","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0895-4356(00)00305-X","article-title":"Are randomized clinical trials good for us (in the short term)? Evidence for a \u201ctrial effect\u201d","volume":"54","author":"Braunholtz","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"2024100721243506900_ehae564-B33","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"2024100721243506900_ehae564-B34","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","article-title":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial","volume":"400","author":"Schlaich","year":"2022","journal-title":"Lancet"},{"key":"2024100721243506900_ehae564-B35","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1056\/NEJMoa1803180","article-title":"Effect of systolic and diastolic blood pressure on cardiovascular outcomes","volume":"381","author":"Flint","year":"2019","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehae564\/59633146\/ehae564.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehae564\/59633146\/ehae564.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T17:24:44Z","timestamp":1728321884000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/45\/38\/4124\/7745627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":35,"journal-issue":{"issue":"38","published-online":{"date-parts":[[2024,9,1]]},"published-print":{"date-parts":[[2024,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehae564","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10,7]]},"published":{"date-parts":[[2024,9,1]]}}}